Former Kite duo given free rein of Pfizer's CAR-T assets

3 April 2018

A start-up has in-licensed the allogeneic CAR-T portfolio of the world’s largest pharma company in a deal that grabbed the attention of the drugmaking world on Tuesday.

Pfizer has agreed the asset contribution agreement with Allogene Therapeutics, a company that was set up by two of the most successful figures in biotech and attracted one of the largest Series A financings in the industry’s history.

Allogene was co-founded by Arie Belldegrun and David Chang, who were chief executive and chief medical officer at Kite Pharma, a company behind one of the world’s first CAR-T therapies that was bought by biotech giant Gilead Sciences (Nasdaq: GILD) in August of 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK